Apigenin Induces Apoptosis and Blocks Growth of Medroxyprogesterone Acetate-Dependent BT-474 Xenograft Tumors

Hormones and Cancer

Volumn 3, Issue 4, 2012, Pages 160-171

  Mafuvadze, Benford ^a   Liang, Yayun ^a   Besch Williford, Cynthia ^b   Zhang, Xu ^a   Hyder, Salman M ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APIGENIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MEDROXYPROGESTERONE ACETATE; OSTEOCLAST DIFFERENTIATION FACTOR; PROGESTERONE RECEPTOR; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BLOOD FLOW; BREAST TUMOR; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MAMMARY GLAND; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; APIGENIN; APOPTOSIS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MEDROXYPROGESTERONE ACETATE; MICE; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; PROGESTERONE CONGENERS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863197873     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-012-0114-x     Document Type: Article

References (53)

1. Narod SA (2011) Hormone replacement therapy and the risk of breast cancer. Nat Rev Clin Oncol 8: 669-676.
2. Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J National Cancer Inst 92: 328-332.
3. Chlebowski RT, Anderson GL, Gass M et al (2010) Writing group for Women's Health Initiative Investigators. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304: 1719-1720.
4. Clarke CL, Sutherland RL (1990) Progestin regulation of cellular proliferation. Endocr Rev 11: 266-301.
5. Aupperlee M, Kariagina A, Osuch J, Haslam SZ (2005-2006) Progestins and breast cancer. Breast Dis 24: 37-57.
6. Hyder SM, Chiappetta C, Stancel GM (2001) Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells. Int J Cancer 92: 469-473.
7. Tsai S, Stefanick ML, Stafford RS (2011) Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause 18: 385-392.
8. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT et al (2007) The decrease in breast cancer incidence in 2003 in the United States. N Engl J Med 356: 1670-1674.
9. Ereman RE, Prebil LA, Mockus M, Koblick K, Orenstein F, Benz C, Clarke CA (2010) Recent trends in hormone therapy utilization and breast cancer incidence rates in the high incidence population of Marin County, California. BMC Publ Health 10: 228.
10. Clarke CA, Glasse SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ (2006) Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 24: e49-e50.
11. Hyder SM, Murthry L, Stancel GM (1998) Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res 58: 392-395.
12. Joshi PA, Jackson HW, Beristain AG et al (2010) Progesterone induces adult mammary stem cell expansion. Nature 465: 803-807.
13. Lanari C, Molinolo AA (2002) Progesterone receptors-animal models and cell signaling in breast cancer: diverse activation pathways for the progesterone receptor possible implications for breast biology and cancer. Breast Cancer Res 4: 240-243.
14. Benakanakere I, Besch-Williford C, Schnell J, Brandt S, Ellersieck MR, Molinolo A, Hyder SM (2006) Natural and synthetic progestins accelerate 7, 12-dimethylbenz[a]anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats. Clin Cancer Res 12: 4062-4071.
15. McGowan EM, Clarke CL (1999) Effects of overexpression of progesterone receptor A on endogenous progestin-sensitive endpoints in breast cancer cells. Mol Endocrinol 13: 1657-1671.
16. Schramek D, Leibbrandt A, Sigl V et al (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468: 98-102.
17. Gonzalez-Suarez E, Jacob AP, Jones J et al (2010) RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468: 103-107.
18. Kariagina A, Xie J, Leipprandt JR, Haslam SZ (2010) Amphiregulin mediates estrogen, progesterone and EGFR signaling in the normal rat mammary gland and in hormone-dependent rat mammary cancers. Horm Cancer 1: 229-244.
19. Patel D, Shukla S, Gupta S (2007) Apigenin and cancer chemoprevention: progress, potential and promise. Int J Oncol 30: 233-245.
20. Mafuvadze B, Benakanakere I, Lopez Perez FR, Besch-Williford C, Ellersieck MR, Hyder SM (2011) Apigenin prevents development of medroxyprogesterone acetate-accelerated 7, 12-dimethylbenz (a) anthracene-induced mammary tumors in Sprague-Dawley rats. Cancer Prev Res 4: 1316-1324.
21. Liang Y, Besch-Williford C, Brekken RA, Hyder SM (2007) Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating anti-tumor therapeutics. Cancer Res 67: 9929-9936.
22. Liang Y, Benakanakere I, Besch-Williford CB, Hyder RS, Ellersieck M, Hyder SM (2010) Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenografts in nude mice. Menopause 17: 1040-1047.
23. El Etreby MF, Liang Y (1998) Effect of antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice. Breast Cancer Res Treat 49: 109-117.
24. Burcombe R, Wilson GD, Dowsett M, Khan I, Richman PI, Daley F, Detre S, Makris A (2006) Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Res 8: R31.
25. Sun P, Ren X, Zhang H, Li X, Cai S, Ye K, Li X (2003) Serum from rabbit orally administered cobra venom inhibits growth of implanted hepatocellular carcinoma cells in mice. World J Gastroenterol 9: 2441-2444.
26. Saal LH, Holm K, Maurer M, Memeo L, Su T et al (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65: 2554-2559.
27. Way T, Kao M, Lin J (2004) Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/akt-dependent pathway. J Biol Chem 279: 4479-4489.
28. Dennis AP, Lonard DM, Nawaz Z, O'Malley BW (2005) Inhibition of the 26S proteasome blocks progesterone receptor-dependent transcription through failed recruitment of RNA polymerase II. J Steroid Biochem Mol Biol 94: 337-346.
29. Ellmann S, Sicht H, Thiel F et al (2009) Estrogen and progesterone receptors: from molecular structures to clinical targets. Cell Mol Life Sci. doi: 10. 1007/s00018-009-0017-3.
30. Chen D, Landis-Piwowar KR, Chen MS, Dou QP (2007) Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts. Breast Cancer Res Treat 9: R80.
31. Wang QR, Yao XQ, Wen G, Fan Q, Li Y, Fu XQ, Li CK, Sun XG (2011) Apigenin suppresses the growth of colorectal cancer xenografts via phosphorylation and up-regulated FADD expression. Oncol Lett 2: 43-47.
32. Zhao AG, Zhao HL, Jin XJ, Yang LD (2002) Effects of Chinese jianpi herbs on cell apoptosis and related gene expression in human gastric cancer grafted onto nude mice. World J Gastroenterol 8: 792-796.
33. Hsueh C, Kelsen D, Schwartz GK (1998) UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced in a sequence dependent manner. Clin Cancer Res 4: 2201-2206.
34. Henkels KM, Turchi JJ (1999) Cisplatin-induced apoptosis proceeds by caspase-3 dependent and independent pathways in cisplatin-resistant and sensitive human ovarian cancer cell lines. Cancer Res 59: 3077-3083.
35. Vargo MA, Voss OH, Poustka F, Cardounel AJ, Grotewold E, Doseff AI (2006) Apigenin-induced-apoptosis is mediated by the activation of PKCdelta and caspases in leukemia cells. Biochem Pharmacol 72: 681-692.
36. Zheng P, Chiang L, Lin C (2005) Apigenin induced apoptosis through p53-dependent pathway in human cervical carcinoma cells. Life Sci 76: 1367-1379.
37. Korkaya H, Paulson A, Iovino F, Wicha MS (2008) HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27: 6120-6130.
38. Le X-F, Eiqun Mao W, Lu C, Thornton A, Heymach JV, Sood AK, Bast RC Jr (2008) Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress Her2. Cell Cycle 7: 3747-3758.
39. Liang Y, Hyder SM (2005) Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects. Endocrinology 146: 3632-3641.
40. Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier-Hayes DJ (2001) Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 85: 273-278.
41. Horwitz KB, Sartorius CA (2008) Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab 93: 3295-3298.
42. Ujiki MB, Ding X, Salabat MR, Bentrem DJ, Golkar L, Milam B, Talamonti Bell RH, Iwamura T, Adrian TE (2006) Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest. Mol Cancer 5: 76.
43. Zhao M, Ma J, Zhu H-Y, Du Z, Xu Y, Yu X (2011) Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90. Mol Cancer 10: 104.
44. Magklara A, Brown TJ, Diamandis EP (2002) Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3. Int J Cancer 100: 507-514.
45. Lee T, Seng S, Sekine M, Hinton C, Fu Y, Avraham HK, Avraham S (2007) Vascular Endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med 4: e186.
46. Su J, Yen C, Chen P, Chuang S, Hong C, Kuo I, Chen H, Hung M, Kuo M (2007) The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer 96: 541-545.
47. Bottino MC, Cerliani JP, Rojas P, Giulianelli S, Soldati R, Mondillo C et al (2011) Classical membrane progesterone receptors in murine mammary carcinomas: agonistic effects of progestins and RU-486 mediating rapid non-genomic effects. Breast Cancer Res Treat 126: 621-636.
48. Petrie WK, Hovey RC (2011) A local basis for progesterone action during mammary tumorigenesis-no longer RANK and file. Breast Cancer Res 13: 301.
49. Tanos T, Brisken C (2011) High hopes for RANKL: will the mouse model live up to its promise? Breast Cancer Res 13: 302.
50. Di Carlo C, Tommaselli GA, Gargano V, Sammartino A, Bifulco G, Tauchmanova L, Colao A, Nappi C (2007) Effects of estrogen-progestin on serum levels of RANKL, osteoprotegerin, osteocalcin, leptin, and ghrelin in postmenopausal women. Menopause 14(1): 38-44.
51. Aupperlee MD, Drolet AA, Durairaj S, Wang W, Schwartz RC, Haslam SZ (2009) Strain-specific differences in the mechanisms of progesterone regulation of murine mammary gland development. Endocrinology 150: 1485-1494.
52. Gupta S, Afaq F, Mukhtar H (2001) Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem Biophys Res Commun 287: 914-920.
53. Klijn JG, de Jong FH, Bakker GH, Lamberts SW, Rodenburg CJ, Alexieva-Figusch J (1989) Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res 49: 2851-2856.